Quinoxaline Piperidine Compounds for ORL-1 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic and acute pain often rely on opioid analgesics, which can have significant side effects and do not effectively target the orphanin FQ/nociceptin (OFQ) receptor, limiting their efficacy and safety.
Innovation Solution
Development of Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds that exhibit affinity and agonist or antagonist activity at the ORL-1 receptor, as well as activity at µ, κ, or δ receptors, offering a new approach for pain management with potentially fewer side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid analgesics are used to treat chronic and acute pain, then pain relief is achieved, but side effects increase and efficacy is limited due to lack of selective targeting
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (cyclic urea or lactam substituents on quinoxaline-type piperidine cores) that confer selective affinity for the ORL-1 receptor. This structural specificity enables the drug to act locally on the intended target (ORL-1) while avoiding non-specific binding to other receptors, thereby achieving effective pain relief with reduced side effects.
Solution Approach 2:
The patent introduces the ORL-1 receptor as an intermediary target between the administered compound and the pain relief effect. By selectively modulating ORL-1 receptor activity rather than directly acting on multiple opioid receptors, the compound achieves pain relief through a more selective pathway, reducing off-target effects and improving the therapeutic profile.
2Adaptability or versatility
If non-selective opioid receptor ligands are used, then broad receptor coverage (μ, κ, δ) is achieved, but selectivity for ORL-1 receptor is lost
Solution Approach 1:
The patent employs local quality by incorporating specific functional groups (cyclic urea at position 1 and lactam at position 2 of the quinoxaline ring) that create a unique molecular recognition pattern. This localized structural feature enables high selectivity for the ORL-1 receptor binding site, distinguishing it from μ, κ, and δ opioid receptors while maintaining effective binding affinity.
Solution Approach 2:
The patent applies parameter changes by modifying key molecular parameters including the introduction of cyclic urea and lactam substituents, optimization of the piperidine ring structure, and adjustment of substituent positions on the quinoxaline core. These parameter modifications collectively enhance ORL-1 receptor selectivity while preserving adequate analgesic activity.
Data Source
AI summary
The disclosure relates to Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein R1, R2, Qa, Y1, Z, A, B, Qx, E, G, J, M, U, W, and a are as defined herein, compositions comprising an effective amount of a Cyclic Urea- or Lactam-Substituted Quinoxal ine-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compound.